Nebenwirkungen · Keppra
Keppra 250 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-090757 · Präparat HOS-084117
The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The adverse reaction profile presented below is based on the analysis of pooledplacebo- controlled clinical trials with all indications studied, with a total of 3416 patients treated with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T12:51:00Z · SHA-256 0c9c2dbe2cf9e6cd5c8f5c1f489027f4a1e9204a5531ad8b866e3bc0e64b2e72 · Passage f596c9519f7ed8270e3725b073bf7beeaf64f4953600f9fc8d5d7e75600e5bee · Zeichen 31–643 im Abschnitt